(Reuters) -The U.S. Food and Drug Administration on Wednesday said it has approved Bayer’s drug for patients with a type of lung cancer that has advanced or spread despite previous treatments.

The drug, branded as Hyrnuo, is approved for non-squamous non-small cell lung cancer (NSCLC) in patients with mutations affecting the HER2 protein, which plays a crucial role in regulating cell growth and development, as identified by an FDA-approved test.

The company did not immediately respond to a Reuters request for comment.

FDA also approved the Life Technologies Corporation’s test as a companion diagnostic device to help detect the mutations in patients who may be eligible for Bayer’s drug.

Bayer’s oral drug belongs to a class of drugs known as kinase inhibitors, which block the action of p

See Full Page